Clinical Trials Browser

Diabetes Mellitus, Carcinoma, Hepatocellular

Esophageal Neoplasms

Carcinoma, Non-Small-Cell Lung

Unresectable Stage III Non-small Cell Lung Cancer

Colorectal Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Recurrence, Lymphoma, Extranodal NK-T-Cell

Small Cell Lung Carcinoma

Carcinoma, Hepatocellular

Carcinoma, Non-Small-Cell Lung

Advanced Solid Tumor

Nasopharyngeal Carcinoma

Nasopharyngeal Neoplasms

Tongue Squamous Cell Carcinoma

Neoplasm Metastasis

Gastric Cancer Peritoneal Metastases

Extensive Stage Lung Small Cell Cancer

Digestive System Neoplasms

Colonic Neoplasms

Esophageal Squamous Cell Carcinoma

Urinary Bladder Neoplasms, Neoplasms

Colorectal Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Esophageal Squamous Cell Carcinoma

Gastric Cancer Stage

Carcinoma, Non-Small-Cell Lung

Lymphoma, Follicular

Esophageal Neoplasms

Esophageal Neoplasms

Small Cell Lung Carcinoma

Esophageal Neoplasms, Stomach Neoplasms

Biliary Tract Neoplasms, Cholangiocarcinoma

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Stomach Neoplasms

Urinary Bladder Neoplasms

Nasopharyngeal Carcinoma

Gastric/Gastroesophageal Junction Adenocarcinoma

Hodgkin Disease, Recurrence

Carcinoma, Non-Small-Cell Lung

Squamous Cell Carcinoma of Head and Neck

Non-Muscle Invasive Bladder Neoplasms

Carcinoma, Non-Small-Cell Lung

Breast Neoplasms

Rectal Neoplasms

Colorectal Neoplasms

Carcinoma, Non-Small-Cell Lung

Clinical Trials

Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes

MRD2START

Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC

BEACON-Lung

TRIUNITE06

A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma

Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin

EpiRev-NKT

A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer

A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence

FMT-LUNG

Study of KRAS-Specific Vaccine in Patients With KRAS-Mutated Solid Tumors

Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma

Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma

Lingual Nerve Disruption to Augment Neoadjuvant Chemoimmunotherapy in Locally Advanced Tongue Cancer

ATARI-PDAC

A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10

Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer

IP rmhTNF-NC + Tislelizumab + Palliat RT for GIT Tumor Malignant Ascites After Failed Std Tx

Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer

A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma

Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer Patients

Efficacy Study of Digoxin Combined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal Cancer

WGc-0201 Plus Tislelizumab in HCC With High Risk of Recurrence and Metastasis After Radical Therapy

Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Treatment

Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma

Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ Cancer

A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC

A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL

Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma

The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ EC

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

TisGCS for BTC

An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung Cancer

Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer

A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.

A Phase II Study of TPF With PD-1 Inhibitor Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma

Tislelizumab Combined with SOX Regimen in the Treatment of Locally Advanced Gastric Cancer/gastroesophageal Junction Adenocarcinoma

BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma

Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer

OSCC

SPRING

A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk.

Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC

Chidamide and PD-1 Inhibitor Plus Anlotinib for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed

Application of PD-1 Monoclonal Antibody in Combination With IL-2 and CapeOX in Organ Preservation Therapy for Ultra-Low Localized Advanced Rectal Cancer

Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases

Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC